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The broad-spectrum anthelmintic drug ivermectin (IVM) activates and stabilizes an
open-channel conformation of invertebrate chloride-selective glutamate receptors
(GluClRs), thereby causing a continuous inflow of chloride ions and sustained membrane
hyperpolarization. These effects suppress nervous impulses and vital physiological
processes in parasitic nematodes. The GluClRs are pentamers. Homopentameric
receptors assembled from the Caenorhabditis elegans (C. elegans) GluClα (GLC-1)
subunit can inherently respond to IVM but not to glutamate (the neurotransmitter). In
contrast, heteromeric GluClα/β (GLC-1/GLC-2) assemblies respond to both ligands,
independently of each other. Glutamate and IVM bind at the interface between adjacent
subunits, far away from each other; glutamate in the extracellular ligand-binding
domain, and IVM in the ion-channel pore periphery. To understand the importance of
putative intersubunit contacts located outside the glutamate and IVM binding sites,
we introduced mutations at intersubunit interfaces, between these two binding-site
types. Then, we determined the effect of these mutations on the activation of the
heteromeric mutant receptors by glutamate and IVM. Amongst these mutations, we
characterized an α-subunit point mutation located close to the putative IVM-binding
pocket, in the extracellular end of the first transmembrane helix (M1). This mutation
(αF276A) moderately reduced the sensitivity of the heteromeric GluClαF276A/βWT
receptor to glutamate, and slightly decreased the receptor subunits’ cooperativity
in response to glutamate. In contrast, the αF276A mutation drastically reduced the
sensitivity of the receptor to IVM and significantly increased the receptor subunits’
cooperativity in response to IVM. We suggest that this mutation reduces the efficacy of
channel gating, and impairs the integrity of the IVM-binding pocket, likely by disrupting
important interactions between the tip of M1 and the M2-M3 loop of an adjacent
subunit. We hypothesize that this physical contact between M1 and the M2-M3 loop
tunes the relative orientation of the ion-channel transmembrane helices M1, M2 and
M3 to optimize pore opening. Interestingly, pre-exposure of the GluClαF276A/βWT
mutant receptor to subthreshold IVM concentration recovered the receptor sensitivity
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to glutamate. We infer that IVM likely retained its positive modulation activity by
constraining the transmembrane helices in a preopen orientation sensitive to glutamate,
with no need for the aforementioned disrupted interactions between M1 and the M2-M3
loop.
Keywords: Cys-loop receptors, GluCls, ligand-gated ion channels, ivermectin, parasitic nematodes
INTRODUCTION
Chloride-selective glutamate receptors (GluClRs) are pentameric
glutamate (Glu)-gated chloride channels unique to invertebrates
(Wolstenholme, 2012). These receptors belong to the Cys-loop
receptor superfamily of transmembrane oligomers that open an
intrinsic ion-channel pore upon binding of neurotransmitters
such as, acetylcholine (ACh; Karlin, 2002; Lester et al., 2004;
Taylor et al., 2007; Taly et al., 2009; Boulin et al., 2012;
Sine, 2012; Chatzidaki and Millar, 2015; Dineley et al., 2015;
Stokes et al., 2015; Corradi and Bouzat, 2016), serotonin
(Lummis, 2012; Kesters et al., 2013), γ-aminobutyric acid
(GABA; Zheleznova et al., 2009; Akk and Steinbach, 2011;
Morlock and Czajkowski, 2011; Spurny et al., 2012; Liang and
Olsen, 2014; Seljeset et al., 2015) glycine (Gly; Betz et al.,
1999; Breitinger and Becker, 2002; Colquhoun and Sivilotti,
2004; Betz and Laube, 2006; Harvey et al., 2008; Sivilotti, 2010;
Lynagh and Lynch, 2012b; Schaefer et al., 2013; Langlhofer
and Villmann, 2016), histamine (Hardie, 1989; Gisselmann
et al., 2002; Zheng et al., 2002) or Glu (Wolstenholme, 2012).
GluClRs are specific targets for ivermectin (IVM), a macrocyclic
lactone widely used as an anthelmintic drug to treat filarial
diseases like onchocerciasis (river blindness), which is caused
by Onchocerca volvulus, and elephantiasis (lymphatic filariasis)
that is caused by Wuchereria bancrofti, Brugia malayi, Brugia
timori and Brugia pahangithat. These diseases afflict hundreds
of millions of people worldwide, mainly in equatorial Africa
(Crump and Omura, 2011; Campbell, 2012). IVM is also
broadly used in cattle, swine and pets to kill gastrointestinal
roundworms, lungworms, grubs, sucking lice and mange mites
(Geary, 2005).
IVM acts as an agonist that keeps the ion-channel pore of the
GluClR continuously open (Cully et al., 1994; Etter et al., 1996;
Dent et al., 1997; Vassilatis et al., 1997; Li et al., 2002; Slimko
et al., 2002). Since the GluClR is chloride selective, IVM causes
sustained hyperpolarization across postsynaptic membranes in
parasitic nematodes. This long-lasting effect eventually leads to
suppression of locomotion (Cook et al., 2006); inhibition of
the pharyngeal muscle activity, which interrupts with feeding
behavior (Geary et al., 1993; Brownlee et al., 1997; Dent et al.,
2000); and interruption of secretion processes in the parasite that
are crucial for evading the host immune system (Moreno et al.,
2010; reviewed in Geary andMoreno, 2012;Wolstenholme, 2012;
Wolstenholme et al., 2016).
Notably, IVM activates and/or potentiates a few vertebrate
Cys-loop receptors, like GABA-, and Gly-gated Cl− channels
(Williams and Risley, 1982; Olsen and Snowman, 1985; Sigel and
Baur, 1987; Krusek and Zemková, 1994; Adelsberger et al., 2000;
Shan et al., 2001; Zheng et al., 2002; Pless and Lynch, 2009b;
Lynagh and Lynch, 2012a; Ménez et al., 2012; Wang and Lynch,
2012) and the α7 cationic ACh-gated channel (Krause et al.,
1998; Collins and Millar, 2010), though with much higher drug
concentrations than in GluClRs. IVM can also activate the P2X
ATP-gated ion channel belonging to a different family of ligand-
gated ion channels (Khakh et al., 1999; Priel and Silberberg, 2004;
Silberberg et al., 2007; Habermacher et al., 2016).
Genes (glc-1 and glc-2) encoding two GluClR homologous
subunits, GluClα (GLC-1; also named GluClα1) and GluClβ
(GLC-2), were firstly cloned from the non-parasitic nematode
C. elegans (Cully et al., 1994). Later, additional genes encoding
subunits of Glu-gated chloride channels were cloned from
C. elegans (Yates et al., 2003) and other invertebrates (Lynagh
et al., 2015) like, parasitic worms (Delany et al., 1998;
Jagannathan et al., 1999; Dufour et al., 2013; Lynagh et al.,
2014), insects (Eguchi et al., 2006; Dong et al., 2013; Furutani
et al., 2014; Kita et al., 2014; Meyers et al., 2015; Wu et al.,
2017), crustaceans (Cornejo et al., 2014), and mollusk (Kehoe
et al., 2009). In several cases, a single subunit was found
to form a functional homomeric receptor–channel that can
be gated by both Glu and IVM independently. For example,
the GluClα2 (AVR-15) subunit of C. elegans (Dent et al.,
1997), the DrosGluCl-α subunit of Drosophila melanogaster
(Cully et al., 1996), the GluClα2B subunit of H. contortus
(McCavera et al., 2009), the MdGluClα subunit of Musca
domestica (Eguchi et al., 2006), the GluCl exon-3 variants of
Bombyx mori (Furutani et al., 2014), and the AgGluCl-a1 of
Anopheles gambiae (Meyers et al., 2015). In contrast, when
expressed in Xenopus oocytes, the C. elegans GluClα subunit
(GLC-1) forms homomeric receptors that can be activated by
IVM but not by Glu, whereas the C. elegans GluClβ subunit
(GLC-2) forms homomeric receptors that can be activated by
Glu but not by IVM (Cully et al., 1994; Vassilatis et al., 1997;
Li et al., 2002; Daeffler et al., 2014). On the other hand, a
heteromeric GluClR consisting of the C. elegans α (GLC-1)
and β (GLC-2) subunits can be activated by both Glu and
IVM independently (Cully et al., 1994; Etter et al., 1996; Dent
et al., 1997; Vassilatis et al., 1997; Li et al., 2002; Slimko et al.,
2002).
The differential responses of the homomeric C. elegans
GluClα or GluClβ receptor assemblies suggest that the binding
sites for Glu and IVM are uncoupled and, possibly, the
conformational changes underlying channel opening by IVM
are different from those underlying opening by Glu. Yet, Glu
elicits current responses in homomeric C. elegans GluClαRs
when applied after activation by IVM, indicating that IVM
binding to the homomeric C. elegans GluClαR induces a
conformational change that couples Glu binding at GluCl α/α
intersubunit interfaces to the ion-channel gate (Etter et al., 1996).
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FIGURE 1 | Structural characteristics of a GluCl receptor. (A) Two of five
subunits of the homopentameric GluClαcrystR [Protein Data Bank (PDB) ID
code 3RIF] are shown from the side in light and dark gray colors. Wide gray
horizontal lines mark the putative membrane borders. The four coupling loops
and the pre-M1 linker are colored as shown in (B,C). Glu and ivermectin (IVM)
are shown as space-filling models with carbon, oxygen and nitrogen atoms
colored in yellow, red and blue, respectively. They are bound at the α/α
intersubunit interface far away from each other: Glu in the extracellular
ligand-binding domain, and IVM in the upper part of the pore-domain
periphery, between M1 (of the light gray subunit) and M3 (of the dark gray
subunit). Hydrogen atoms were removed for better viewing. (B) Residues
relevant to this study are shown as spheres with carbon atoms having the
ribbon color, and oxygen, nitrogen and hydrogen atoms in red, blue and white
colors, respectively. Only S237 is shown with its backbone atoms. (C) E273
(of the pre-M1 linker) is sandwiched between Q243 (gray) and S332 (green)
that are located in the β9 strand and the M2-M3 loop of the adjacent subunit,
respectively. Only the side chains of the three residues are shown, as
space-filling models with their hydrogen atoms. E273 is colored with purple
carbons, red oxygens and white hydrogens.
Recently, it was demonstrated that a C. elegans heteromeric
GluClα/β receptor, whose β subunits were engineered to carry
the α-subunit’s Cys and β8β9 loops (Figure 1A), readily responds
to Glu, with no need of IVM pre-association (Degani-Katzav
et al., 2016). Since the GluCl α and β subunits share the same
β1β2-loop sequence, all the coupling loops originating from
the ligand-binding domain of this heteromeric mutant receptor
(β1β2, Cys and β8β9 loops in each subunit) have the sequence
of the α subunit. Hence, it was concluded that these α-subunit’s
coupling loops are inherently capable of transducing motions
in the Glu-binding site to gating motions in the ion-channel
pore (Degani-Katzav et al., 2016). Moreover, a mutation inside
the IVM binding pocket (αL279W) increased the sensitivity of
the C. elegans GluClα/βR to both IVM and Glu (Degani-Katzav
et al., 2016), suggesting that the IVM and Glu binding sites in
the C. elegans GluClα/β heteromeric receptor are allosterically
coupled.
To understand the importance of putative intersubunit
contacts located outside the Glu and IVM binding sites, we
introduced mutations at intersubunit interfaces, between these
two binding-site types. To this end, we have used the three
dimensional (3-D) structure of the GluClαcryst receptor as
a guiding tool for substituting residues in the C. elegans
GluClα (GLC-1) subunit (Figures 1, 2; Table 1) that was
co-expressed with the wild type C. elegans GluClβ (GLC-2)
subunit to form heteromeric receptors. Then, we determined by
electrophysiological measurements the effect of these mutations
on the activation of the wild type and mutant receptors by
glutamate and IVM.
MATERIALS AND METHODS
Generation of cDNA Constructs
The cDNA encoding the GluClα subunit was a kind
gift from Dr. Henry A. Lester (optGluCl alpha EYFP;
Plasmid #15104 in Addgene), and it was used to prepare
the cDNA of the C. elegans GluClαWT subunit (GLC-
1; see UniProt entry G5EBR3 for the ORF sequence).
The cDNA encoding the C. elegans GluClβWT subunit
(GLC-2; see UniProt entry Q17328 for the ORF sequence)
was prepared by reverse transcription of total C. elegans
RNA and PCR amplification of the relevant ORF, which
was subsequently cloned into a pcDNA3.1 vector. Single or
double site-specific mutations were introduced as previously
by using the QuikChange site-directed mutagenesis kit
(Stratagene; Pittel et al., 2010, 2015). The entire ORF of
all mutants was sequenced and subcloned into an original
pcDNA3.1 vector.
Preparation of Cells for
Electrophysiological Experiments
Chinese hamster ovary (CHO) cells were cultured as previously
(Bar-Lev et al., 2011) in Dulbecco’s Modified Eagle Medium
(DMEM) containing 10% fetal calf serum, 2 mM glutamax,
100 Units/ml penicillin G and 100 µg/ml streptomycin, and
grown in 5% CO2 at 37◦C under 90%–95% humidity. The
cells were seeded on glass coverslips (13-mm diameter) placed
in a 24-multiwell plate. Picrotoxin (5 µM) was added to the
cells immediately before transfection, to prevent chloride fluxes
through the expressed GluCl channels due to the presence
of glutamate in the fetal calf serum. For the expression of
GluCl receptors, cells were transiently co-transfected with
pcDNA3.1 plasmids containing the ORFs of interest using
transit-LT1 transfection reagent (Mirus, Madison, WI, USA),
according to the manufacturer’s protocol. The cDNAs encoding
the C. elegans GluClα (GLC-1) or its mutated versions and
the GluClβ (GLC-2) subunits (200–600 ng per well) were
used at 1:1 ratio. The pIRES-CD8 plasmid (200 ng per well)
was added to enable the visualization of the expressing cells
by beads coated with anti-CD8 antibodies (Invitrogen). For
high-level expression of the GluClαF276A/βWTmutant receptor
in experiments assigned to determine its IVM-EC50, we used
the X-tremeGENE HP DNA Transfection Reagent (Roche Life
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FIGURE 2 | Sequence alignments of the coupling loops, pre-M1 linker and the first transmembrane segment (M1) in a few Cys-loop receptors.
Colored amino acids in the first row match the colors in Figure 1. Asterisks indicate highly conserved amino acids. GluCl_cryst, a truncated α subunit used for
crystallization and 3-D structure determination by X-ray crystallography (PDB ID 3RIF). CE, Caenorhabditis elegans; HS, Homo sapiens; MM, Mus musculus
(mouse); TM, Torpedo marmorata (Marbled electric ray). UniProt Knowledgebase entry codes: CE_GluClR_alpha, G5EBR3; CE_GluClR_beta, Q17328;
HS_GABAaR_alpha1, P14867; HS_GABAaR_rho1, P24046; HS_GlyR_alpha1, P23415; HS_GlyR_alpha3, O75311; HS_nAChR_alpha1, P02708;
MM_nAChR_alpha1, P04756; TM_nAChR_alpha, P02711; TM_nAChR_beta, Q6S3I0; TM_nAChR_gamma, Q6S3H9; TM_nAChR_delta, Q6S3H8;
HS_nAChR_alpha7, P36544; MM_5HT3aR, P23979.
Science). Recordings were performed 72–96 h following the
transfection.
Whole-Cell Patch Clamp Recordings
Whole-cell patch clamp recordings were performed as described
previously (Bar-Lev et al., 2011) in CHO cells that were prepared
as detailed above. The normal external solution (NES) contained
(in millimolar): 140 NaCl, 2.8 KCl, 2 CaCl2, 2 MgCl2, 10 glucose
and 10 HEPES, adjusted to pH 7.35 with NaOH (310 mOsm/L).
The pipette solution contained (inmillimolar): 130 KCl, 4MgCl2,
4 Na2ATP, 1 EGTA and 10 HEPES, adjusted to pH 7.35 with
KOH (290 mOsm/L). The osmolarity of these solutions was
maintained by adding sucrose. The electrode resistance was
6–10MΩwhen filled with the pipette solution. External solutions
were applied onto the cell by using the VC-77SP fast-step system
(Warner Instruments, Hamden, CT, USA) combined with N2
pressure of 3–4 psi to produce laminar flow of the external
solution onto the patched cell. All measurements were performed
at room temperature. The currents were measured with an
Axopatch 200B patch-clamp amplifier (Molecular Devices,
Sunnyvale, CA, USA) and a Digidata 1440A interface (Molecular
Devices). Acquisition of recording data was performed at 2.5 kHz
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 April 2017 | Volume 10 | Article 92
Degani-Katzav et al. Structure-Function Relationships in a GluClR









P192 P131 Cys loop P162
Y194 Y133 Cys loop R164
S236 S175 β8β9 loop G206
S237 S176 β8β9 loop S207
S238 S177 β8β9 loop D208
Q243 Q182 β9 I213
E273 E212 Pre-M1 Q244
F276 F215 M1 Y247
P330 P269 M2-M3 loop P301
S332 S271 M2-M3 loop S303
I334 I273 M2-M3 loop V305
1UniProt Knowledgebase entry codes of the full-length subunits used in this study.
GluClα, GLC-1; GluClβ, GLC-2. 2 ID number in the RCSB PDB.
and recordings were low-pass filtered at 1 kHz, through a
four-pole Bessel filter. The pClamp 10 software (Molecular
Devices) was used for data acquisition. To establish I/V relations,
Glu-EC50 concentrations were applied for 800 ms. Five-hundred
milliseconds after the application started (which is also after the
current reached to its peak at −60 mV), the voltage was stepped
from −60 mV to −80 mV for 50 ms followed by a 250-ms-long
voltage ramp ranging from−80 mV to +80 mV.
Data Analysis
Dose-response curves were fitted to the data points by a





where I is the current response, Imax is the maximal current
response, EC50 is the agonist effective concentration that elicits
50% of maximal current response, [Glu] is the concentration of
glutamate, and nH is the Hill coefficient.
Statistical Analyses
Unless otherwise stated, P values correspond to unpaired,
two-tailed Student’s t-tests. Note that values were rounded to the
closest decimal figure; however, the non-rounded numbers were
used for the statistical analyses.
RESULTS
Activation of GluClR Assemblies by IVM
and Glu
All the GluCl receptor assemblies mentioned below originate
from the C. elegans GluClα (GLC-1) and GluClβ (GLC-2)
subunits; so, the species name is avoided hereafter. We have
recently shown that CHO cells transfected with the wild type
GluClα subunit (αWT) alone display very weak responses to
10mMGlu but robust responses to 500 nM IVM (Degani-Katzav
et al., 2016). It was also shown that CHO cells transfected with
the wild type GluClβ subunit (βWT) alone display very weak,
rare responses to 10 mMGlu (Degani-Katzav et al., 2016). Others
also reported irresponsiveness to Glu in human embryonic
kidney (HEK) cells transfected with the wild type GluClβ subunit
alone (Slimko et al., 2002; Frazier et al., 2013; Daeffler et al.,
2014). Most recently, we succeeded to obtain responses of a
few hundred picooamperes in CHO cells transfected with the
WT GluClβ subunit alone using the X-tremeGENE HP DNA
Transfection Reagent (Roche Life Science); but, in this case, we
challenged the cells with 100 mM Glu, and only 4 of 46 cells
responded (Degani-Katzav et al., 2017). In contrast, CHO cells
co-transfected with both WT GluCl α and β subunits commonly
display robust responses to both Glu and IVM (Degani-Katzav
et al., 2016). These results are summarized in Table 2. We
therefore deduce that common, robust responses to Glu recorded
in CHO cells co-transfected with mutant GluClα and wild type
GluClβ subunits reflect the function of heteromeric GluClα/βR
complexes (Table 2).
Effects of Site-Specific Mutations on the
Sensitivity of the Heteromeric GluClR to
Glu
Previous functional studies with various Cys-loop receptor
mutants have shown that the M2-M3 loop is involved in the
gating process (Campos-Caro et al., 1996; Lynch et al., 1997;
Boileau and Czajkowski, 1999; Grosman et al., 2000; Bera et al.,
2002; Absalom et al., 2003; Kash et al., 2003; Bouzat et al., 2004,
2008; Grutter et al., 2005; Law et al., 2005; Lee and Sine, 2005;
Lummis et al., 2005; Reeves et al., 2005; Sala et al., 2005; Xiu et al.,
2005; Jansen and Akabas, 2006; Jha et al., 2007; Lee et al., 2008,
2009; Chang et al., 2009; Paulsen et al., 2009; Perkins et al., 2009;
Pless and Lynch, 2009b; Wiltfong and Jansen, 2009; Yamodo
et al., 2010; Hamouda et al., 2011; Zhang et al., 2011, 2013;
Dellisanti et al., 2013; Mnatsakanyan and Jansen, 2013; Scott
et al., 2015; Bertozzi et al., 2016). Hence, in this study we refrained
from substituting amino acids in the M2-M3 loop or amino acids
that, according to the X-ray crystal structure of the GluClαcrystR,
might directly contribute to the bond network of the β1β2,
Cys and β8β9 loops with the M2-M3 loop (Hibbs and Gouaux,
2011). Instead, following a careful inspection of the 3-D structure
of the GluClαcrystR (Hibbs and Gouaux, 2011), we mutated
residues in the full-length GluClα subunit that were expected
to be involved in intersubunit contacts between the Cys and
β8β9 loops (Figure 1B and Table 1). We also mutated residues
in the pre-M1 and M1 regions that might have direct contacts
with the M2-M3 loop of the adjacent subunit (Figures 1B,C and
Table 1).
According to the GluClαcrystR structure (PDB code 3RIF),
αP192 and αY194 of the Cys loop form van der Waals
interactions across the intersubunit α/α interface with αS237 of
the β8β9 loop in the neighboring subunit (Hibbs and Gouaux,
2011; Figure 1B; see Table 1 for numbering in the GluClαcryst
subunit). Replacement of αP192 by either E, M or Y did not
substantially change the EC50 and Hill coefficient (nH) for
Glu (Figure 3A and Table 2), which may indicate that the
contact at this position is not important or it is preserved by
the substituting amino acids. Furthermore, replacing αY194 by
the homologous residue of the GluClβ subunit created a
GluClαY194R/βWT receptor that displays wild type behavior in
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TABLE 2 |Q5 Macroscopic activation properties of the wild type and mutant GluClα/β receptors.
GluClR subunit combination Glu activation properties Glu (EC50 conc.) IVM (500 nM)
EC50, mM ANOVA nHa Amplitude (nA) Amplitude (nA)b
αWT NDc – NDc NDc 1.0 ± 0.3 (14)
βWT NDc – NDc NDc 0.0 ± 0.0 (10)
αWT/βWT 1.5 ± 0.1 (27) – 1.6 ± 0.1 3.2 ± 0.3 (35) 1.8 ± 0.1
αP192E/βWT 2.4 ± 0.3 (9) ns 1.5 ± 0.1 3.1 ± 0.7 (15) 1.7 ± 0.3
αP192M/βWT 3.5 ± 0.2 (6) ∗ 1.6 ± 0.1 3.2 ± 0.6 (11) 1.4 ± 0.2
αP192Y/βWT 1.7 ± 0.4 (5) ns 1.5 ± 0.1 2.1 ± 0.3 (6) 1.2 ± 0.2
αY194R/βWT 1.7 ± 0.2 (7) ns 1.5 ± 0.1 5.9 ± 2.3 (6) 2.1 ± 0.5
αSSSd→GSD/βWT 1.2 ± 0.2 (10) ns 1.3 ± 0.1 2.9 ± 0.6 (7) 1.8 ± 0.4
αE273R/βWT 6.3 ± 1.1 (9) ∗∗ 1.5 ± 0.1 2.2 ± 0.5 (9) 1.0 ± 0.2
αF276A/βWT 9.3 ± 0.9 (7) ∗∗ 1.3 ± 0.1 3.1 ± 0.5 (15) 0.2 ± 0.03
αF276W/βWT 5.5 ± 0.6 (9) ∗∗ 1.5 ± 0.1 3.0 ± 0.4 (19) 1.2 ± 0.2
EC50, half-maximal effective concentration of Glu. nH, Hill coefficient of activation by Glu. Number of determinations is provided in parentheses. aSame cells as used for
the EC50. bSame cells as used for the amplitudes obtained by EC50 concentrations (conc.) of Glu. cNot determined due to very small currents recorded in response to
10 mM Glu. dPositions 236–238. Data are mean ± SEM. ANOVA, one-way analysis of variance performed with Dunnett’s multiple comparison test for the EC50 values.
Asterisks indicate a statistically significant difference in comparison with the GluClαWT/βWT receptor, with probabilities of ∗0.01 < P < 0.05 and ∗∗0.001 < P < 0.01; ns,
does not differ significantly from the GluClαWT/βWT receptor (P > 0.05). Same ANOVA analysis for the nH values indicates no significant difference between the various
mutant and wild type receptors (P > 0.05), except for the αSSS→GSD/βWT and αF276A/βWT mutants where P < 0.05.
terms of the EC50 and Hill coefficient for Glu (Figure 3A and
Table 2).
As said, αS237 of the β8β9 loop interacts with the αP192 and
αY194 of the Cys loop of the adjacent subunit. So, we wished
to assess whether the sequence difference between the α and
β subunits (αSS237S vs. βGS207D; Figure 2) imparts different
conformation-dependent contact with functional relevance.
Hence, we also replaced the αSSS sequence by the homologous
βGSD sequence. However, this triple-site substitution exerted
no (or minor) effects on the EC50 and Hill coefficient of
the GluClα[SSS→GSD]/βWT receptor for Glu (Figure 3A and
Table 2).
According to the GluClαcrystR, αE273 is situated in the
pre-M1 linker and its side chain forms van derWaals interactions
with αQ243 of the β9 strand and αS332 of the M2-M3 loop
in the adjacent subunit (Hibbs and Gouaux, 2011; Figure 1C).
Hence, αE273 might play a role in ion-channel gating by
transducing movements of the outer β-sheet to the M2-M3 loop
of the neighboring subunit. However, only moderate 4.2-fold
increase in the Glu-EC50 and no change in the Hill coefficient
of activation by Glu were observed for the GluClαE273R/βWT
receptor (Figure 3A and Table 2). These observations indicate
that the charge at position α273 does not play a substantial role
in the receptor–channel gating process; otherwise, a larger effect
would have arisen.
According to the crystal structure of the homomeric
GluClαcrystR, αF276 is located in the upper helical turn of
the first transmembrane helix (M1) close to the IVM binding
pocket, but it does not have any contacts with IVM (Figure 1B).
In the GluClαcrystR, αF276 forms van der Waals interactions
with αP330 located in the M2-M3 loop of the neighboring
subunit (Hibbs and Gouaux, 2011; Figure 1B). Changing
the bulky hydrophobic Phe at position α276 to the small
hydrophobic alanine residue increased the Glu-EC50 of the
GluClαF276A/βWT mutant receptor by 6.2-fold and slightly
decreased the Hill coefficient of activation by Glu (Figure 3A
and Table 2). In contrast, substituting a very large hydrophobic
residue at this position to give the GluClαF276W/βWT mutant
receptor increased the Glu-EC50 by 3.7-fold, with no substantial
change in the Hill coefficient of activation by Glu (Figure 3A and
Table 2).
The rationale for using a positive membrane voltage in
these experiments was initially based on previous experiments
showing that the wild type heteromeric GluClα/β receptor
provides an I/V curve that weakly rectifies outwardly when
heterologically expressed in Xenopus oocytes (Cully et al., 1994).
As such, the currents at +60 mV were larger by ∼4.5 folds
than the currents at −60 mV (Cully et al., 1994). Since it
was important for us to achieve robust responses at Glu-EC50
concentrations when we further determined IVM/Glu peak
amplitude ratios (see below), we measured responses at +60 mV.
However, here we have used approximately equimolar extra-
and intracellular chloride ion concentrations (150.8 mM and
138 mM, respectively), whereas the extracellular and calculated
intracellular chloride-ion concentrations used in the Xenopus
oocyte system were 122.6 mM and 33 mM, respectively (Cully
et al., 1994). Accordingly, here, the currents measured at
+60 mV are larger by only ∼1.4 folds than the currents
measured at −60 mV for both, the GluClαWT/βWT and
the mutant GluClαF276A/βWT receptors that display close-
to-linear I/V relations (Figure 3B). It should therefore be
emphasized that, hereafter, the behavior of the WT and mutant
receptors were compared under exactly the same experimental
conditions.
Sensitivity of Heteromeric GluClR Mutants
to IVM Relatively to their Responsiveness
to Glu-EC50 Concentrations
To compare between the sensitivities of the wild type and
mutant GluClα/β receptors to IVM, we used the Glu-EC50
concentrations and analyzed the relative IVM/Glu responses.
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FIGURE 3 | Sensitivity of GluClα/β receptors to Glu. (A) Representative
current traces measured in cells co-transfected with the indicated subunits
(two upper rows). Horizontal bars correspond to 1-s applications of Glu in
millimolar concentrations as indicated below the bars. Recordings were
performed at +60 mV. The lowest row of this panel shows Glu dose-response
curves for receptors assembled from the GluClα subunits indicated in the
insets and the GluClβWT subunit. Curves were fitted to the averaged data
points with a nonlinear regression using the Hill equation (Equation 1)
(r2 > 0.99). Error bars correspond to SEM. (B) Current-voltage (I/V ) relations
obtained upon the application of Glu-EC50 concentrations over a voltage ramp
lasting 250 ms in cells expressing the indicated subunits (see “Materials and
Methods” Section). The I+60 mV/I-60 mV ratios calculated for the GluClαWT/βWT
and the GluClαF276A/βWT receptors are 1.3 ± 0.03 and 1.44 ± 0.1
(mean ± SEM), respectively; P = 0.14 for three determinations each.
To this end, only cells that showed robust responses to Glu
at +60 mV, were subsequently challenged by 500 nM IVM
(e.g., Figures 4A,B). As such, we ascertained that weak responses
to IVM are not due to low expression levels; rather they might
reflect a reduced receptor sensitivity to IVM (e.g., Figure 4B).
Yet, determination of IVM-EC50 values were required for
mutants showing reduced IVM/Glu response ratio (see further
below). The responses to IVM were measured at −60 mV, a
membrane voltage that keeps the cell stable for a long time
application. Then, in each cell, the peak current obtained upon
FIGURE 4 | Sensitivity of GluClα/β receptors to IVM relatively to their
responsiveness to Glu-EC50 concentrations. (A,B) Representative current
traces elicited in response to EC50 concentrations of Glu (left, +60 mV) and
500 nM IVM (right, −60 mV). Cells were co-transfected with the indicated
subunits. (C) Histogram corresponding to the ratio of IVM-elicited over
Glu-elicited current peak amplitudes. EC50 concentrations of Glu (Table 2)
and 500 nM IVM were used. Cells were co-transfected with the GluClα
subunits indicated below the bar graph together with the GluClβWT subunit.
∗∗∗P < 0.0001; no statistical difference was observed between the other
mutants and the wild type receptor (P > 0.06). The number of cells is
indicated in parentheses above the graph’s bars.
IVM application was divided by the peak current obtained
upon Glu application. As such, variability that could have
emerged due to differences in receptor expression levels was
avoided.
Figure 4B shows that the heteromeric GluClαF276A/βWT
receptor robustly responds to the Glu-EC50 concentration,
but weakly responds to IVM (500 nM). Compared to the
GluClαWT/βWT receptor, the IVM/Glu response ratio
of the GluClαF276A/βWT receptor decreased by ∼7-fold
(Figure 4C, purple and green bars, respectively). All
other mutations in the GluClα subunit had no statistically
significant effect on the sensitivity to IVM, as determined
relatively to their responsiveness to Glu-EC50 concentrations
(Figure 4C).
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The current shown in Figure 4A (right) declines in the
presence of IVM, despite that IVM stabilizes an open channel
conformation. It should therefore be noted that previous studies
demonstrated that the decline of the inward current (outflow
of Cl− ions) conveyed by heteromeric GluClα/βRs is due to
a decrease in the electrochemical driving force acting on the
chloride ions during the time window of the recording (Slimko
et al., 2002; Degani-Katzav et al., 2016).
Potentiation by IVM of the
GluClαF276A/βWT Receptor’s Responses
to Glu
Replacing the bulky αF276 in the tip of M1 by the much
smaller side chain of alanine (GluClαF276A/βWT receptor) can
be envisioned to disrupt the multiple van der Waals contacts
that the native Phe had with P330 of the M2-M3 loop in
the neighboring subunit (Figure 1B). So, as a result, it is
possible that M1, M2 and M3 dislocate one with respect to
another, which could make the receptor opening process more
difficult. Since IVMbinds at the intersubunit interface andmakes
extensive contacts with the M1 and M3 of adjacent subunits
(Hibbs and Gouaux, 2011), we examined how the drug affects
the macroscopic activation of the GluClαF276A/βWT mutant
receptor by Glu.
It was previously shown that 5 nM IVM potentiates the
Glu-sensitive currents of the wild type GluClα/βR by ∼5-fold,
as measured in Xenopus oocytes (Cully et al., 1994). For an
appropriate reference in CHO cells, we first determined the
capacity of IVM to potentiate the response of the wild type
heteromeric receptor to Glu. To this end, 0.3 mM Glu was
initially applied to obtain a weak current response (Figure 5A,
upper trace, leftmost response). This Glu concentration activates
∼7% of the GluClαWT/βWT receptor population, as can be
calculated based on the Glu dose-response curve (Figure 3A).
This weak response increased by ∼6-fold when 0.3 mM Glu was
applied again shortly after exposure of the cell to 7 nM IVM
(Figure 5A, upper trace and the inset). The same application
protocol was employed for the mutant GluClαF276A/βWT
receptor with two exceptions. First, we used 1 mM Glu, which
activates ∼5% of the mutant receptor population. Second, we
used 50 nM IVM that is ∼7 times the IVM concentration
used for the GluClαWT/βWT receptor. This IVM concentration
reflects the ∼7-fold decrease in the IVM/Glu response ratio of
the GluClαF276A/βWTmutant receptor (Figure 4C). Figure 5A
(lower trace and the inset) shows that in the GluClαF276A/βWT
receptor, IVM potentiated the response to Glu by ∼18-fold.
Notably, the response of the GluClαF276A/βWTreceptor to IVM
was very weak, but could clearly be visualized uponmagnification
(see Supplementary Figure S1).
In order to quantify the potentiation effect of IVM more
accurately, we first exposed the expressing cell to the low
IVM concentrations mentioned in Figure 5A, and as soon
as the IVM-elicited current reached to the steady state, we
challenged the expressing cell with increasing Glu concentrations
(e.g., Figures 5B,C). The corresponding Glu dose-response
curves are shown in Figure 5D (EC50 and nH values are
FIGURE 5 | Effect of pre-exposure to IVM on the activation of GluClα/β
receptors by Glu. (A) Representative current traces of the potentiation effect
exerted by IVM on Glu-elicited responses in cells co-transfected with the
indicated subunits. Glu concentrations before and after IVM application:
0.3 mM (upper trace); 1 mM (lower trace). IVM concentrations: 7 nM (upper
trace); 50 nM (lower trace). Supplementary Figure S1 shows magnification of
the lower trace. Inset, fold-potentiation for the GluClαWT/βWT (5.9 ± 0.6) and
GluClαF276A/βWT (17.9 ± 1.8) receptors. Data are mean ± SEM. The
number of determinations is indicated in white; ∗∗∗P < 0.001.
(B,C) Representative current traces elicited by increasing Glu concentrations
after IVM pre-application. The time of delay between the end of IVM
(Continued)
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FIGURE 5 | Continued
application and the beginning of Glu application was 20 s. IVM
concentrations, as in (A). Oblique lettering indicate the expressed subunits.
(D) Glu dose-response curves for experiments exemplified in (B,C). Dashed
curves correspond to measurements performed after pre-exposure to IVM in
cells expressing the GluClαWT/βWT (purple) or GluClαF276A/βWT (green)
receptors. Curves were fitted as in Figure 3A (r2 > 0.98). Error bars
correspond to SEM. Continuous curves correspond to measurements
performed without pre-exposure to IVM (taken from Figure 3A). Glu-EC50
after pre-exposure to IVM: 0.3 ± 0.03 mM for the GluClαWT/βWT receptor,
and 1.1 ± 0.1 mM for the GluClαF276A/βWT receptor (P < 0.0001). Hill
coefficients of activation by Glu for the WT and mutant receptors (dashed
curves): 1.2 ± 0.07 and 1.5 ± 0.03, respectively (P < 0.003). Statistical
significance for the Hill coefficients before vs. after exposure to IVM:
GluClαWT/βWT receptor, P < 0.001; and GluClαF276A/βWT receptor,
P < 0.04. (E) Fold decrease in Glu-EC50 observed after pre-exposure to IVM.
Data in (D,E) are mean ± SEM; number of determinations in white. ∗∗
0.001 < P < 0.005.
detailed in the legend). Evidently, in both the wild type and
mutant receptors the Glu dose-response curves have shifted
to the left (dashed lines) due to the pre-application of IVM
(Figure 5D). In addition, after pre-exposure to IVM, the Hill
coefficient for Glu slightly increased in the case of the mutant
GluClαF276A/βWT receptor, whereas it slightly decreased in
the case of the GluClαWT/βWT receptor (Figure 5D and its
legend). Figure 5E indicates that the IVM-induced decrease in
Glu-EC50 is ∼5-fold and ∼8.5-fold for the GluClαWT/βWT
and GluClαF276A/βWT receptors, respectively; despite that the
mutant receptor displayed weaker responsiveness to IVM than
the wild type receptor (e.g., Figure 5A, lower trace vs. upper trace;
Figure 5C vs. Figure 5B).
Concentration-Response Relationships
Indicate that αF276 is Important for IVM
Accommodation
The results presented in the previous sections may suggest
that the αF276A mutation increases the Glu-EC50 value by
affecting allosterically the conformation of the Glu-binding
pockets and thereby changing the mode of Glu accommodation.
However, another possibility is that the channel has become
generally less easy to open with no essential change in
the mode of Glu binding, while IVM retains its positive
modulation activity. To understand the impact of the αF276A
mutation further, we analyzed the IVM concentration-response
relationships for the GluClαWT/βWT and GluClαF276A/βWT
receptors. Because IVM currents are irreversible, we established
the IVM concentration-response relationships by successively
applying increasing IVM concentrations as has previously been
performed, for example, in the case of the GlyR (Lynagh and
Lynch, 2010; Lynagh et al., 2011). Since the responses of the
mutant GluClαF276A/βWT receptor to 500 nM IVM were weak
(e.g., Figure 4B, right; Table 2), in these experiments we have
used a more powerful transfection reagent and raised the amount
of cDNA used in cell transfections (see ‘‘Materials and Methods’’
Section). Figures 6A,B show representative current traces for
the GluClαWT/βWT and GluClαF276A/βWT receptors. Such
experiments were used to establish the IVM dose-response
FIGURE 6 | Responses of GluClα/β receptors to cumulative
concentrations of IVM. (A,B) Representative current traces measured in
cells co-transfected with the indicated subunits. Horizontal bars correspond to
applications of IVM in increasing nanomolar concentrations, as indicated
above the bars. Recordings were performed at −60 mV. (C) IVM
dose-response curves for experiments exemplified in (A,B). The Curves were
fitted to the averaged data points with a nonlinear regression using the Hill
equation (Equation 1) (r2 > 0.98). Error bars correspond to SEM. IVM-EC50
values for the GluClαWT/βWT and GluClαF276A/βWT receptors are
40 ± 10 nM and 802 ± 170 nM, respectively (mean ± SEM of
six determinations for each receptor type; P = 0.01). Hill coefficients of
activation by IVM for the GluClαWT/βWT and GluClαF276A/βWT receptors are
1.5 ± 0.2 and 3.5 ± 0.40, respectively (mean ± SEM; P = 0.001).
curves shown in Figure 6C. These dose-response curves indicate
that the IVM-EC50 of the GluClαWT/βWT receptor (40 nM)
was 20-fold lower than that of the GluClαF276A/βWT receptor
(802 nM; see statistical analysis in the legend to Figure 6C).
The wild type and mutant receptors also differ in their
Hill coefficient of activation by IVM, which was found to
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be 1.5 for the GluClαWT/βWT receptor and 3.5 for the
GluClαF276A/βWTmutant receptor (Figure 6C; see statistics in
the legend).
DISCUSSION
In the homomeric GluClαcrystR, large portions of the Cys and
β8β9 loops are situated at the interface between neighboring
subunits, where they directly interact with each other (Hibbs
and Gouaux, 2011; Figure 1A). That is, in an α/α intersubunit
interface, αP192 and αY194 of the Cys loop form van der Waals
interactions with αS237 of the β8β9 loop of the neighboring
subunit (Hibbs and Gouaux, 2011; Figure 1B). Potential
homologous contacts might also exist in the heteromeric
GluClα/βR, at α/β, β/α and α/α intersubunit interfaces.
Replacement of residues in this contact region of the GluClα
subunit by the homologous residues of the GluClβ subunit
(GluClαY194R/βWT and GluClαSSS→GSD/βWT receptors)
exerted no substantial effects on the Glu-EC50 and the receptor
subunits’ cooperativity. These results imply that the Cys–β8β9-
loop contacts at this specific point are either preserved in
the potential heteromeric intersubunit interfaces (α/β or β/α),
or alternatively are not essential for macroscopic activation.
Furthermore, the substitution of GluClαP192 for charged,
uncharged or polar bulky residues appears not to be detrimental
for the conformation of the Cys loop since the Glu-activation
macroscopic properties were not essentially changed (Table 2).
Likewise, the unchanged IVM/Glu response ratio of the
heteromeric GluClRs bearing the αP192E/M/Y and αY194R
mutations (Figure 4C) suggests that the conformation of
the IVM-binding site is not allosterically affected by these
mutations.
According to the GluClαcryst receptor, E273 is located in the
pre-M1 region (Hibbs and Gouaux, 2011) that was previously
shown to carry amino acids involved in the gating process
in other Cys-loop receptors (Boileau and Czajkowski, 1999;
Chang et al., 2003; Hu et al., 2003; Kash et al., 2004; Lee
and Sine, 2005; Xiu et al., 2005; Keramidas et al., 2006; Price
et al., 2007; Purohit and Auerbach, 2007; Wang et al., 2007;
Mercado and Czajkowski, 2008; Cederholm et al., 2009; Lee
et al., 2009; Mukhtasimova et al., 2009; Pless and Lynch, 2009a;
Bruhova and Auerbach, 2010; Hanson and Czajkowski, 2011;
Pless et al., 2011; Wang and Lynch, 2011; Gonzalez-Gutierrez
et al., 2013; Mukhtasimova and Sine, 2013; Shen et al., 2016). In
the GluClαcrystR, αE273 is sandwiched between Q243 located in
the β9 strand of the same subunit and S332 that is located in the
M2-M3 loop of the adjacent subunit (Hibbs and Gouaux, 2011;
Figure 1C). More particularly, the carboxylic oxygens Oε1 and
Oε2 of E273 are located at distances of 3.4 and 3.8 angstroms
from the Cβ atoms of S332 and Q243, respectively; with no
seemingly close opposite charge to pair with. As such, in the
homomeric GluClαcrystR, E273 probably makes van der Waals
interactions with these two residues. Furthermore, it can be
envisioned that upon a slight motion of the outer β-sheet
(which β9 belongs to), the carboxylic oxygens of E273 could
become sufficiently close to form hydrogen bonds with Q243 and
S332. Hence, based on the GluClαcrystR structure (Hibbs and
Gouaux, 2011), E273 could be involved in transduction of
neurotransmitter-binding energy to the channel gate via the
M2-M3 loop. Yet, it appears here that the charge at this position
does not have a fundamental role in such a process as the αE273R
mutation increased the Glu-EC50 by only 4.2-fold. Hence, the
moderate effect of this mutation may be attributed to a slight
change in the van der Waals (or potential hydrogen) bond
network that the replaced (native) residue at this position is
involved in.
These observations were quite surprising for us because in
various other Cys-loop receptors the residue at the homologous
position does play a role in the gating process, despite that it is
not conserved. For example, in the mouse 5HT3AR, when R245
(the homologous position of GluClαE273; Figure 2) was mutated
to A or E, larger impacts on the receptor function have been
observed (Hu et al., 2003; Price et al., 2007). This arginine of the
mouse 5HT3AR was suggested to pair ionically with a glutamate
residue located on the β9 strand (homologous to GluClαQ243),
so as to transduce agonist binding to channel gating (Price et al.,
2007). Mutations introduced at the homologous position in the
mouse nAChR α1 subunit (L230 in Figure 2) increased the gating
equilibrium constant relatively to the wild type receptor (Purohit
and Auerbach, 2007). Mutations were also introduced at the
homologous position in the human nAChR α1 subunit (L255 in
Figure 2). The latter indicated the existence of energetic coupling
between this leucine from the pre-M1 region, αF180 and
αF182 from the Cys-loop, and αL318 from the M2–M3 loop
(amino acid numbering according to Figure 2; Lee et al., 2009).
So, it was suggested that the β1-β2 and Cys loops bridge the
pre-M1 region and M2-M3 loop to transduce agonist binding
into channel gating (Lee et al., 2009). Taken together, in relation
to this position, it appears that the invertebrate GluClα/βR differs
from the aforementioned vertebrate Cys-loop receptors, since its
α273 position plays a minor role in gating. Notably, the αE273R
mutation did not change the IVM/Glu response ratio (Figure 4C)
although, according to the GluClαcrystR structure, E273 interacts
with S332 of the M2-M3 loop—very close to I334 that makes a
contact with IVM.
EC50 depends both on the ligand-binding affinity and
efficacy of gating (Colquhoun and Farrant, 1993). Since the
20-fold increase in IVM-EC50 of the GluClαF276A/βWTmutant
receptor (Figure 6) was accompanied by moderate 6.2-fold
increase in its Glu-EC50 (Table 2), we suggest that the αF276A
mutation reduced the efficacy of channel gating with likely no
allosteric effect on the Glu-binding affinity. This suggestion is
also supported by the observation that the αF276A mutation
caused a slight change in the Hill coefficient of activation by
Glu (Table 2), but dramatically changed the Hill coefficient of
activation by IVM (Figure 6). An inevitable question therefore
emerges; why would the sensitivity to IVM decrease significantly
due to a mutation of a residue that does not interact directly with
IVM (at least according to the 3-D structure of the GluClαcryst
receptor)?
The mutation in the heteromeric GluClαF276A/βWT
receptor is located in the first helical turn of M1, outside but
close to the IVM-binding pocket that is located between M1 and
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M3 of neighboring subunits. According to the GluClαcrystR
3-D structure, the side chain of the native amino acid (αF276)
forms multiple van der Waals interactions with αP330 of the
M2-M3 loop of the neighboring subunit (Hibbs and Gouaux,
2011; Figure 1B). αP330 is not conserved throughout Cys-loop
receptors, but the GluClβ subunit also has a proline residue at the
homologous position in its M2-M3 loop (Figure 2). Therefore,
substituting GluClαF276 for an alanine would probably eliminate
the Phe–Pro interactions at potential α/α and β/α intersubunit
interfaces in the heteromeric GluClαF276A/βWT receptor.
Such elimination might enable more freedom for M1 to move
relatively to M3 and thereby could change the position of
amino acids that interact with IVM. This interpretation is
supported by two sets of experiments. First, in a screen for
the sensitivity of the various receptors to IVM relatively to
their responsiveness to Glu-EC50 concentrations, the ratio of
IVM/Glu peak amplitudes was found to be significantly lower
for the GluClαF276A/βWT mutant receptor than for the wild
type and the other mutant receptors (Figure 4C). Second,
independently of the responsiveness to Glu, determinations of
IVM-EC50 values indicate that the mutant GluClαF276A/βWT
receptor is much less sensitive to IVM than the GluClαWT/βWT
receptor (as discussed above). Furthermore, the wild type and
mutant receptors greatly differ in their Hill coefficients of
activation by IVM (nH = 1.5 and 3.5 respectively; Figure 6C).
It therefore appears that the binding of two IVM molecules
is required to achieve full macroscopic activation of the
GluClαWT/βWT receptor, whereas the binding of at least
three IVM molecules is required to fully activate the mutant
GluClαF276A/βWT receptor. Taken together, we suggest that
αF276 plays an important role in IVM accommodation because
it interacts with the M2-M3 loop and thereby contributes to the
stabilization of the IVM-binding pocket between M1 and M3 of
adjacent subunits.
The loss of a contact between the tip of M1 and the
M2-M3 loop might possibly dislocate M1, M2 and M3 and
thereby reduce the channel-gating efficacy. If this is actually
the case in the GluClαF276A/βWT mutant receptor, then
constraining M1 in respect to M3 by IVM is anticipated to
improve the efficacy of channel gating. Indeed, despite that the
GluClαF276A/βWT mutant receptor is 20-fold less sensitive to
IVM than the GluClαWT/βWT receptor, it was sufficient to
increase the pre-applied IVM concentration only by ∼7 times,
in order to get larger potentiation of Glu currents in the mutant
receptor (∼18-fold) than in the wild type receptor (∼6-fold;
Figure 5A, inset). Moreover, an increase of the pre-applied
IVM concentration by ∼7-fold improved (reduced) the Glu-
EC50 of the mutant receptor to a larger fold-extent than in the
WT receptor (∼8.5-fold vs. 5-fold, respectively; Figures 5D,E).
Notably, those differences in IVM potentiation were obtained
even though the pre-applied IVM activated the mutant to lesser
extent than the wild type receptor (Figure 5). Taken together,
the capability of IVM to bridge between M1 and M3 of adjacent
subunits, likely by forming multiple interactions with these
transmembrane segments, largely compensates for the reduction
in channel-gating efficacy. We suggest that the reduction in
channel-gating efficacy is most likely due to the loss of the
aforementioned interaction between the tip of M1 and the
M2-M3 loop in the mutant receptor. We further hypothesize
that, in the presence of a subthreshold IVM concentration,
M1 and M3 of the mutant receptor likely adopts WT-like
conformation that is typical of a preopen state sensitive to Glu.
Noteworthy, in comparison with the effect of the αF276A
mutation, the αF276W mutation exerted weaker effect on the
Glu-EC50, no effect on the Hill coefficient for Glu (Figure 3A
and Table 2), and no effect on the IVM/Glu response ratio
(Figure 4C). We therefore suggest that a tryptophan residue at
position α276 interacts with the M2-M3 loop of the neighboring
subunit akin to the native phenylalanine.
It is also noteworthy that, based on previous functional
studies, motions of M1 and M3 were suggested to take place
during activation in other Cys-loop receptors. Using cysteine
substitutions and disulfide crosslinking experiments with a
GABAAR, demonstrated that the extracellular ends of M1 and
M3 of the adjacent α1 and β2 subunits get closer to each other
upon activation (Bali et al., 2009). Other functional studies
showed that, the susceptibility of amino acids in M1 to various
chemical modifications is changed following the transition of
resting ACh- and GABA-gated Cys-loop receptors to their active
state (Akabas and Karlin, 1995; Yu et al., 2003; Arevalo et al.,
2005; Li et al., 2006; Pandhare et al., 2012). It is of interest to note
that IVM activatesmammalianGABA-gated chloride channels as
well (Williams and Risley, 1982; Olsen and Snowman, 1985; Sigel
and Baur, 1987; Krusek and Zemková, 1994; Adelsberger et al.,
2000; Lynagh and Lynch, 2012b; Ménez et al., 2012), possibly by
binding to a pocket between M1 and M3 of adjacent subunits
akin to the GluClRs. So, this potential IVM-binding pocket
might overlap the well-characterized binding site of GABAARs
for the intravenous anesthetic agent etomidate (Li et al., 2006,
2010; Olsen and Li, 2011; Chiara et al., 2012; Stewart et al.,
2013a,b, reviewed in Olsen et al., 2014). Hence, the current
study might be relevant to further research that aims at better
understanding of how certain general anesthetics modulate the
activity of GABA-gated Cys-loop receptors.
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